Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 2064147

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 2064147

Global RNA Targeting Small Molecule Drug Discovery Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The global RNA targeting small molecule drug discovery market size is expected to reach USD 16.02 Billion in 2034 from USD 2.67 Billion in 2025, growing at a CAGR of 22.03 during 2026-2034.This market is gaining substantial momentum as pharmaceutical companies increasingly explore RNA-focused therapies for treating complex diseases. RNA targeting small molecules offer unique advantages by influencing disease pathways that are difficult to address using traditional drug discovery methods. Growing research activities in oncology, neurological disorders, and rare genetic diseases are driving investments in this field. The expanding understanding of RNA biology and advancements in molecular screening technologies are further supporting market development.

The increasing prevalence of chronic diseases worldwide is creating strong demand for innovative therapeutic approaches. Pharmaceutical and biotechnology companies are investing heavily in RNA-targeted drug discovery platforms to identify novel treatment options with improved efficacy and safety profiles. Strategic collaborations between research institutions and industry players are accelerating clinical development activities. Additionally, advances in computational biology, artificial intelligence, and high-throughput screening technologies are improving the identification and optimization of RNA-targeting compounds.

Future growth is expected to be driven by expanding clinical pipelines and rising regulatory support for innovative therapies. Continued progress in precision medicine and personalized healthcare will create new opportunities for RNA-targeted treatments. As researchers uncover additional RNA structures and disease-related targets, the market is likely to witness a growing number of drug candidates entering clinical trials. The combination of scientific advancements and increasing healthcare investments will support long-term market expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

  • Cancer
  • Infectious Diseases
  • Metabolic Diseases
  • Neurological Diseases
  • Others

By End Use

  • Pharmaceutical and Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others

COMPANIES PROFILED

  • ACCENT THERAPEUTICS, Anima Biotech Inc., Arrakis Therapeutics, AstraZeneca, Epics Therapeutics, Expansion Therapeutics, F. Hoffmann-La Roche Ltd, PTC Therapeutics, Inc., Ribometrix, LES LABOAbivax, AC immune, eFFECTOR TherapeuticsRATOIRES SERVIER, Skyhawk Therapeutics, STORM Therapeutics, H3 Biomedicine
Product Code: VMR112118435

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET: BY INDICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Indication
  • 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET: BY END USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End Use
  • 5.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Indication
    • 6.2.2 By End Use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Indication
    • 6.3.2 By End Use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Indication
    • 6.4.2 By End Use
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Indication
    • 6.5.2 By End Use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Indication
    • 6.6.2 By End Use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 ACCENT THERAPEUTICS
    • 8.2.2 Anima Biotech Inc
    • 8.2.3 Arrakis Therapeutics
    • 8.2.4 AstraZeneca
    • 8.2.5 Epics Therapeutics
    • 8.2.6 Expansion Therapeutics
    • 8.2.7 F. Hoffmann-La Roche Ltd
    • 8.2.8 PTC TherapeuticsInc
    • 8.2.9 Ribometrix
    • 8.2.10 LES LABOAbivax
    • 8.2.11 AC Immune
    • 8.2.12 EFFECTOR TherapeuticsRATOIRES SERVIER
    • 8.2.13 Skyhawk Therapeutics
    • 8.2.14 STORM Therapeutics
    • 8.2.15 H3 Biomedicine
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!